IU study: Vaccine protects most cancer patients from COVID-19, but risk remains higher for patients with blood cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID-19. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough infections after receiving the vaccine.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login